Nkarta, Inc.

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif. , July 25, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the promotions of Ralph Brandenberger, PhD, to Chief Technical Officer and Yvonne Li, MBA, to Chief Administrative Officer.

Nkarta Announces Key Senior Leadership Team Appointments

Fate Therapeutics

IVERIC bio Inc

Karuna Therapeutics Inc

Madrigal Pharmaceuticals

Seagen

Takeda Pharmaceutical

One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration approval. If that happens, Jefferies analyst Chris Howerton believes the treatment should have “no issue” topping annual sales of $1 billion, reported BioPharma Dive.

Trial Results Set to Make or Break Small-Cap Pharma Stocks

Investors who like Fate Therapeutics Inc. ( FATE , Financial) should love Nkarta Inc. ( NKTX , Financial).

Nkarta Stock a Bargain Compared to Fate Therapeutics

The consensus price target hints at a 209.4% upside potential for Nkarta, Inc. (NKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 209% Upside in Nkarta, Inc. (NKTX): Here's What You Should Know

The market has favorably appreciated Nkarta's recent readout of its NKX101 and NKX019 drug candidates, with the share price more than doubling. I see a huge disconnect between analyst targets and the actual share price, possibly due to the market's lack of insight in the highly innovative nature of the science.

Nkarta: A Promising Natural Killer Cell Play

Nkarta, Inc. (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Nkarta, Inc. (NKTX) a New Buy Stock

The average of price targets set by Wall Street analysts indicates a potential upside of 383.4% in Nkarta, Inc. (NKTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Nkarta, Inc. (NKTX) Climb 383% to Reach the Level Wall Street Analysts Expect?

SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the appointment of David R. Shook, MD, as Vice President, Clinical Development. Dr. Shook is a practicing pediatric hematologist, oncologist, and transplanter, and an early pioneer of natural killer (NK) cell therapy. He currently directs Nkarta's co-lead clinical programs, NKX101 and NKX019. In his expanded role, Dr. Shook will lead all clinical development and regulatory activities at Nkarta. Kanya Rajangam, MD, PhD, has resigned as Chief Medical Officer, effective June 5, 2022, and has accepted a position to oversee research and development activities at a private biotechnology company.

Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the first quarter ended March 31, 2022.

Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights

Redbox Entertainment

2 Red-Hot Stocks That Soared More Than 60% in April

NKTX stock is a fast mover, and a recent share-price bump came in the wake of exciting data from a "killer cell" anti-cancer research program. The post Positive Clinical Results Put Nkarta Stock on the Fast Track appeared first on InvestorPlace.

Positive Clinical Results Put Nkarta Stock on the Fast Track

SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced the closing of its previously announced underwritten public offering of 13,333,334 shares of its common stock at a price to the public of $15.00 per share, and the exercise in full by the underwriters of their option to purchase an additional 2,000,000 shares of common stock. The exercise of the underwriters' option brought the total number of shares of common stock sold by Nkarta to 15,333,334 shares and increased the gross proceeds raised in the offering, before deducting underwriting discounts and commissions and offering expenses, to $230 million.

Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares

Some of its early clinical data look much better than expected.

Up 131% in a Day, Is This Hot Stock a Buy?

SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a price to the public of $15.00 per share. The Company has granted the underwriters a 30-day option to purchase up to 2,000,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares in the offering are to be issued and sold by Nkarta.

Nkarta Announces Pricing of Upsized Public Offering of Common Stock

Bargain hunters may want to feast their eyes on a South San Francisco-based biotech focusing on cancer treatments.

Nkarta Scores Huge Gain on Cancer Treatment Results

SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced that it has commenced a proposed underwritten public offering to issue and sell $150 million of shares of its common stock. The Company also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All shares in the offering are to be issued and sold by Nkarta.

Nkarta Announces Proposed Public Offering of Common Stock

Nkarta Inc. (NASDAQ: NKTX) is up 40% after announcing positive preliminary Phase 1 findings from its dose-finding trials of NKX101 and NKX019 in hematological malignancies. NKX101 and NKX019 are two leading chimeric antigen receptor natural killer cell therapies the company is developing for two different sets of hematologic malignancies.

Here is why Nkarta is 40% up

Nkarta (NKTX) stock is rocketing higher on Monday after the company released preliminary data from a Phase 1 clinical trial. The post Why Is Nkarta (NKTX) Stock Soaring 90% Today?

Why Is Nkarta (NKTX) Stock Soaring 90% Today?

Nkarta Inc (NASDAQ: NKTX) has revealed the first human results from its two lead off-the-shelf NK cell therapies, with the high-dose regimens exhibiting multiple complete responses in blood cancer patients.  For NKX101, three patients achieved a complete response (CR) among.

Investors Cheer Nkarta's First NK Cell Data With Multiple Complete Responses

Shares of Nkarta Inc. NKTX, +95.82% skyrocketed 92.8% in very active morning trading, enough to make the stock the biggest gainer and most active listed on major U.S. exchanges, after the biopharmaceutical company announced positive results from a Phase 1 trial of its cancer treatments. The rally comes after the stock closed at a record low of $7.77 on Friday.

Nkarta stock skyrockets on heavy volume after upbeat results from cancer-treatment trial

Biopharmaceutical stock Nkarta Inc (NASDAQ:NKTX) is skyrocketing today, up 91.4% at $14.87 at last check, after the company announced positive preliminary data for two of its experimental cell therapy treatments.

Struggling Biopharma Stock Blasts Higher After Upbeat Data

Shares of Nkarta Inc. NKTX, -2.51% soared 42.7% in premarket trading on Monday after the company reported positive Phase 1 clinical data for two experimental CAR-T therapies. Three of five patients with pre-treated acute myeloid leukemia reported a complete response after undergoing treatment with one of the investigational therapies.

Nkarta's stock jumps 42% after announcing positive Phase 1 data for experimental CAR-T therapies

NKX101 – 3 of 5 patients with relapsed / refractory AML treated with a three-dose regimen consisting of 1B or 1.5B CAR NK cells per dose achieved complete response with full hematologic recovery (60% CR rate); 2 of 3 CRs are MRD negative

Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs

Call scheduled for Monday, April 25, 2022 8:00 a.m. ET

Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2022.

News for Nkarta, Inc. Stock (NKTX)